65649-551 : Relistor 12 mg/.6ml Subcutaneous Injection, Solution


NDC: 65649-551
Labeler: Salix Pharmaceuticals, Inc.
Product Type: Human Prescription Drug
Drug Name:  Relistor
Dosage Form: Subcutaneous Injection, Solution
Application #: NDA021964
Rev. Date: 


NDC Package Codes:

  • 65649-551-02: 1 VIAL, SINGLE‑DOSE IN 1 CARTON (65649‑551‑02) > .6 ML IN 1 VIAL, SINGLE‑DOSE
  • 65649-551-03: 7 BLISTER PACK IN 1 CARTON (65649‑551‑03) > 1 SYRINGE IN 1 BLISTER PACK > .6 ML IN 1 SYRINGE
  • 65649-551-06: 1 BLISTER PACK IN 1 CARTON (65649‑551‑06) > 1 SYRINGE IN 1 BLISTER PACK > .6 ML IN 1 SYRINGE
  • 65649-551-07: 1 BLISTER PACK IN 1 CARTON (65649‑551‑07) > 1 SYRINGE IN 1 BLISTER PACK > .6 ML IN 1 SYRINGE

Active Ingredients:

  • Methylnaltrexone Bromide

Dosage Strength:

  • 12 mg/.6mL

Pharmaceutical Classes:

  • Opioid Antagonist [EPC]
  • Opioid Antagonists [MoA]
  • Quaternary Ammonium Compounds [CS]

Related Products:

Based on records with the same trade name.
  • 65649-150 Relistor 150 mg Oral Tablet by Salix Pharmaceuticals, Inc.
  • 65649-552 Relistor 8 mg/.4ml Subcutaneous Injection, Solution by Salix Pharmaceuticals, Inc.
  • 65649-553 Relistor Kit by Salix Pharmaceuticals, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 65649-551 QR Code

< Prev: 65649-511Next: 65649-552 >

Related Discussions:

Relistor (methylnaltrexone bromide) Reviews
I would like some feedback on Relistor 150 mg. I've been prescribed 3 pills every morning for opioid-induced or seve... 1 reply
Relistor
Does anyone know if there is a pill form of this drug? I am on alot of meds that cause constipation and this sounds like...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.